These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21095265)

  • 1. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY).
    Valgimigli M; Campo G; Percoco G; Monti M; Ferrari F; Tumscitz C; Zuffi A; Colombo F; Kubbajeh M; Cavazza C; Cangiano E; Tebaldi M; Minarelli M; Arcozzi C; Scalone A; Frangione A; Borghesi M; Marchesini J; Parrinello G; Ferrari R
    Am Heart J; 2010 Nov; 160(5):804-11. PubMed ID: 21095265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
    Valgimigli M; Borghesi M; Tebaldi M; Vranckx P; Parrinello G; Ferrari R;
    Eur Heart J; 2013 Mar; 34(12):909-19. PubMed ID: 23315904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
    Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G; Costa F; Ariotti S; Biscaglia S; Campo G; Esposito G; Leonardi S; Vranckx P; Windecker S; Valgimigli M
    Am Heart J; 2016 Apr; 174():95-102. PubMed ID: 26995375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia).
    Campo G; Tebaldi M; Vranckx P; Biscaglia S; Tumscitz C; Ferrari R; Valgimigli M
    J Am Coll Cardiol; 2014 Feb; 63(6):506-12. PubMed ID: 24161321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study.
    Collet JP; Cayla G; Cuisset T; Elhadad S; Rangé G; Vicaut E; Montalescot G
    Am Heart J; 2011 Jan; 161(1):5-12.e5. PubMed ID: 21167334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
    Migliorini A; Valenti R; Marcucci R; Parodi G; Giuliani G; Buonamici P; Cerisano G; Carrabba N; Gensini GF; Abbate R; Antoniucci D
    Circulation; 2009 Dec; 120(22):2214-21. PubMed ID: 19917884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
    Byrne RA; Schulz S; Mehilli J; Iijima R; Massberg S; Neumann FJ; ten Berg JM; Schömig A; Kastrati A;
    Am Heart J; 2009 Apr; 157(4):620-4.e2. PubMed ID: 19332187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
    Spinler SA
    Am J Manag Care; 2009 Mar; 15(2 Suppl):S42-7. PubMed ID: 19355808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial.
    Di Sciascio G; Patti G; Pasceri V; Colonna G; Mangiacapra F; Montinaro A;
    Eur Heart J; 2010 Jun; 31(11):1337-43. PubMed ID: 20363764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    Baber U; Akhter M; Kothari S; Sharma SK; Kini A
    J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel biodegradable polymer-coated, paclitaxel-eluting stent inhibits neointimal formation in porcine coronary arteries.
    Buszman P; Milewski K; Zurakowski A; Pajak J; Liszka Ł; Buszman P; Musioł E; AbuSamra M; Trznadel S; Kałuza G
    Kardiol Pol; 2010 May; 68(5):503-9. PubMed ID: 20491008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between the efficacy of dual antiplatelet therapy and the development of in-stent neointimal hyperplasia in porcine coronary arteries.
    Hemetsberger R; Farhan S; Strehblow C; Sperker W; Pavo I; Petrasi Z; Hemetsberger H; Posa A; Huber K; Glogar D; Gyöngyösi M
    Coron Artery Dis; 2008 Dec; 19(8):635-43. PubMed ID: 19005299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Evaluation of Vessel HEaling After AngiopLasty (REVEAL) trial: rationale, objectives and design.
    Tamburino C; Capodanno D; La Manna A; di Salvo M; Sanfilippo A; Prati F
    J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):53-8. PubMed ID: 19829136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.